Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Merck
Colorcon
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR DILTIAZEM HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Diltiazem Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000478 ↗ Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1990-11-01 To assess the feasibility of and test the methodology for a full-scale clinical trial of therapies for asymptomatic cardiac ischemia.
NCT00000556 ↗ Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1995-03-01 To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007605 ↗ Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm Completed US Department of Veterans Affairs Phase 3 1998-04-01 Atrial fibrillation is the most frequently occurring cardiac arrhythmia, with 1.0-1.5 million cases annually. It is a risk factor for congestive heart failure, and stroke, 75,000 cases of the latter occurring annually in patients with atrial fibrillation. The safety of the most widely used antiarrhythmic agent for this group of patients, quinidine, has been called into question. This study seeks to determine whether two other agents, amiodarone and sotalol, are safe and effective treatments for patients with atrial fibrillation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diltiazem Hydrochloride

Condition Name

Condition Name for Diltiazem Hydrochloride
Intervention Trials
Atrial Fibrillation 11
Hypertension 10
Healthy Subjects 5
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diltiazem Hydrochloride
Intervention Trials
Atrial Fibrillation 14
Hypertension 9
Fissure in Ano 8
Heart Failure 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diltiazem Hydrochloride

Trials by Country

Trials by Country for Diltiazem Hydrochloride
Location Trials
United States 148
Mexico 9
Australia 8
Germany 7
Spain 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diltiazem Hydrochloride
Location Trials
California 10
Texas 7
New York 7
Tennessee 6
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diltiazem Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Diltiazem Hydrochloride
Clinical Trial Phase Trials
Phase 4 23
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diltiazem Hydrochloride
Clinical Trial Phase Trials
Completed 58
Unknown status 16
Recruiting 12
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diltiazem Hydrochloride

Sponsor Name

Sponsor Name for Diltiazem Hydrochloride
Sponsor Trials
Ventrus Biosciences, Inc 5
VA Office of Research and Development 5
AstraZeneca 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diltiazem Hydrochloride
Sponsor Trials
Other 93
Industry 39
U.S. Fed 13
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Express Scripts
Colorcon
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.